VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Documentation of a CF diagnosis                    │ Documentation of a CF diagnosis                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Enrolled in the Cystic Fibrosis Foundation         │ Enrolled in the Cystic Fibrosis Foundation         │     100 │
│ National Patient Registry (CFFNPR) prior to Visit  │ National Patient Registry (CFFNPR) prior to Visit  │         │
│ 1 (US sites only)                                  │ 1 (US sites only)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At the time of Visit 1, there is a plan to         │ At the time of Visit 1, there is a plan to         │     100 │
│ initiate IV antibiotics for a pulmonary            │ initiate IV antibiotics for a pulmonary            │         │
│ exacerbation                                       │ exacerbation                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Performed spirometry at Visit 1 and Visit 2 and    │ Performed spirometry at Visit 1 and Visit 2 and    │     100 │
│ willing to perform spirometry at Visit 3           │ willing to perform spirometry at Visit 3           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Completed the CRISS questionnaire at Visit 1 and   │ Completed the CRISS questionnaire at Visit 1 and   │     100 │
│ Visit 2 and willing to complete the Cystic         │ Visit 2 and willing to complete the Cystic         │         │
│ Fibrosis Respiratory Symptoms Diary (CFRSD)        │ Fibrosis Respiratory Symptoms Diary (CFRSD)        │         │
│ questionnaire at Visit 3                           │ questionnaire at Visit 3                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willing to adhere to a specific treatment duration │ Willing to adhere to a specific treatment duration │     100 │
│ determined by initial response to treatment and    │ determined by initial response to treatment and    │         │
│ subsequent randomization                           │ subsequent randomization                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willing to return for follow up Visit 3            │ Willing to return for follow up Visit 3            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent obtained from the subject │ Written informed consent obtained from the subject │     100 │
│ or subject's legal representative                  │ or subject's legal representative                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous randomization in this study               │ Previous randomization in this study               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with IV antibiotics in the 6 weeks prior │ Treatment with IV antibiotics in the 6 weeks prior │     100 │
│ to Visit 1                                         │ to Visit 1                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Admission to the intensive care unit for current   │ Admission to the intensive care unit for current   │     100 │
│ pulmonary exacerbation in the two weeks prior to   │ pulmonary exacerbation in the two weeks prior to   │         │
│ Visit 2, unless admission was due to a             │ Visit 2, unless admission was due to a             │         │
│ desensitization protocol                           │ desensitization protocol                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pneumothorax in the two weeks prior to Visit 2     │ Pneumothorax in the two weeks prior to Visit 2     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary diagnosis for current hospitalization is   │ Primary diagnosis for current hospitalization is   │     100 │
│ unrelated to worsening lower respiratory symptoms  │ unrelated to worsening lower respiratory symptoms  │         │
│ (e.g., pulmonary clean out, distal intestinal      │ (e.g., pulmonary clean out, distal intestinal      │         │
│ obstruction syndrome (DIOS), sinusitis)            │ obstruction syndrome (DIOS), sinusitis)            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Massive hemoptysis defined as \> 250 cc in a 24    │ Massive hemoptysis defined as > 250 cc in a 24     │     100 │
│ hour period or 100 cc/day over 4 consecutive days  │ hour period or 100 cc/day over 4 consecutive days  │         │
│ occurring in the two weeks prior to Visit 2        │ occurring in the two weeks prior to Visit 2        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current pulmonary exacerbation thought to be due   │ Current pulmonary exacerbation thought to be due   │     100 │
│ to allergic bronchopulmonary aspergillosis (ABPA)  │ to allergic bronchopulmonary aspergillosis (ABPA)  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At Visit 1, receiving ongoing treatment with a     │ At Visit 1, receiving ongoing treatment with a     │     100 │
│ duration of more than 2 weeks with prednisone      │ duration of more than 2 weeks with prednisone      │         │
│ equivalent to \>10mg/day                           │ equivalent to >10mg/day                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of solid organ transplantation             │ History of solid organ transplantation             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Receiving antimicrobial therapy to treat non-      │ Receiving antimicrobial therapy to treat non-      │     100 │
│ tuberculous mycobacterium (e.g., M. abscessus, M.  │ tuberculous mycobacterium (e.g., M. abscessus, M.  │         │
│ avium complex) in the two weeks prior to Visit 2   │ avium complex) in the two weeks prior to Visit 2   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female ≥18 years of age at Visit 1         │ Male or female =18 years of age at Visit 1         │      98 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                              │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Key Inclusion Criteria            │ Documentation of a CF diagnosis            │      34 │
├───────────────────────────────────┼────────────────────────────────────────────┼─────────┤
│ Key Exclusion Criteria            │ Documentation of a CF diagnosis            │      34 │
├───────────────────────────────────┼────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Male or female =18 years of age at Visit 1 │      40 │
╘═══════════════════════════════════╧════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 91.18181818181819
OverAll Ratio: 94.5909090909091
